GENB vs RXRX
GENB: Generate Biomedicines is an AI-powered biotechnology company focused on creating a new generation of programmable protein therapeutics. RXRX: Recursion Pharmaceuticals is a TechBio company using proprietary AI-driven platforms and supercomputing to fundamentally transform the drug discovery and development process.
Side-by-side fundamentals
| Metric | GENB | RXRX | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $13.99 | $3.95 | |
| Market cap | $1.8B | $2.1B | |
| Net margin FY2025, SEC XBRL | n/a | -863.4% | |
| Operating margin FY2025, SEC XBRL | n/a | -867.9% | |
| ROE FY2025, SEC XBRL | n/a | -57.0% | |
| ROA FY2025, SEC XBRL | n/a | -43.7% | |
| Debt / equity as of 2026-09-03 | 0.01 | 0.02 | GENB lower |
| Revenue growth (YoY) as of 2026-09-03 | -37.7% | -15.1% | RXRX higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +23.3% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.21 | 2.56 | |
| 1-year return as of 2026-10-08 close | n/a | -35.1% |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.